Several studies have reported that knockdown of endogenous oncogenic mutant K-Ras in a range of NCSLC and pancreatic cancer cell lines blocks their growth and survival, suggesting that blocking oncogenic K-Ras activity is a valid strategy for anti–K-Ras therapies. Here, KRAS is linked to familial pancreatic carcinoma.